PREGABALIN
| Brand name | LYRICA CR |
|---|---|
| Active ingredient | PREGABALIN |
| Strength | 82.5MG |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | October 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9144559*PED | May 2027 | — |
| 10022447*PED | May 2027 | — |
| 8945620*PED | May 2027 | — |
| 10022447 | November 2026 | use U-2136 |
| 8945620 | November 2026 | product |
| 9144559 | November 2026 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.